Amylin & Takeda suspended the study of pramlintide/metreleptin for obesity

Amylin Pharmaceuticals and Takeda Pharmaceutical announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

What Is the Diabetes Belt?

OraMoist™

| Print | Category | Home

This article originally posted 17 March, 2011 and appeared in Issue 565

Diabetes In Control Advertisers

Cast Your Vote

Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?

View All Polls »

Navigate Diabetes In Control

Cardiovascular CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews GLP-1 Agonist Sheri R. Colberg, PhD SGLT-2

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes

Search Articles On Diabetes In Control

Privacy / Advertising With Us / Contact Us / UBM Medica Network Privacy Policy

Add us to your favorite news reader

DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.